• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A quantitative evaluation of the histological type dependence of the programmed death-ligand 1 expression in non-small cell lung cancer including various adenocarcinoma subtypes: a cross-sectional study.一种对非小细胞肺癌组织学分型与程序性死亡配体 1 表达相关性的定量评估,包括各种腺癌亚型:一项横断面研究。
Jpn J Clin Oncol. 2022 Mar 3;52(3):281-285. doi: 10.1093/jjco/hyab202.
2
Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.肺腺癌亚型的分类与肿瘤细胞程序性死亡配体 1(PD-L1)表达的关联。
Pathol Oncol Res. 2021 Apr 8;27:597499. doi: 10.3389/pore.2021.597499. eCollection 2021.
3
Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma.肺腺癌中肿瘤程序性死亡受体配体1(PD-L1)表达与表皮生长因子受体(EGFR)野生型状态及预后不良的关系
Jpn J Clin Oncol. 2016 Oct;46(10):935-941. doi: 10.1093/jjco/hyw087. Epub 2016 Aug 10.
4
Clinicopathological analysis of programmed death-ligand 1 testing in tumor cells of 325 patients with non-small cell lung cancer: Its predictive and potential prognostic value.325例非小细胞肺癌患者肿瘤细胞程序性死亡配体1检测的临床病理分析:其预测及潜在预后价值
Cesk Patol. 2018 Summer;54(3):137-142.
5
Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.程序性死亡配体 1 及其周围免疫状态对Ⅰ期肺癌的预后影响。
Clin Lung Cancer. 2020 Jul;21(4):e302-e314. doi: 10.1016/j.cllc.2020.01.013. Epub 2020 Jan 27.
6
Molecular profile of non-small cell lung cancer in northeastern Brazil.巴西东北部非小细胞肺癌的分子特征。
J Bras Pneumol. 2019 Jun 3;45(3):e20180181. doi: 10.1590/1806-3713/e20180181.
7
Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.PD-L1表达及PD-L1基因多态性与肺腺癌和肺鳞癌预后不良的相关性
Hum Pathol. 2017 Oct;68:103-111. doi: 10.1016/j.humpath.2017.08.016. Epub 2017 Aug 26.
8
Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.磷酸酶张力蛋白同系物和程序性细胞死亡配体 1 在肺的腺鳞癌中的表达。
Biochem Biophys Res Commun. 2018 Sep 18;503(4):2764-2769. doi: 10.1016/j.bbrc.2018.08.037. Epub 2018 Aug 9.
9
Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.显著核仁与非腺特征是肺腺癌中PD-L1表达的独立预测因素。
Anticancer Res. 2018 Oct;38(10):6003-6008. doi: 10.21873/anticanres.12949.
10
Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.具有小部分肉瘤样成分和多形性癌的非小细胞肺癌与程序性死亡配体 1 的高表达相关。
Pathol Res Pract. 2020 Dec;216(12):153238. doi: 10.1016/j.prp.2020.153238. Epub 2020 Oct 2.

本文引用的文献

1
Association of explanatory histological findings and urinary protein and serum creatinine levels at renal biopsy in lupus nephritis: a cross-sectional study.狼疮肾炎肾活检中组织学解释性发现与尿蛋白和血清肌酐水平的相关性:一项横断面研究。
BMC Nephrol. 2020 Jun 1;21(1):208. doi: 10.1186/s12882-020-01868-9.
2
Molecular features of lung adenocarcinoma in young patients.年轻患者肺腺癌的分子特征。
BMC Cancer. 2019 Aug 6;19(1):777. doi: 10.1186/s12885-019-5978-5.
3
Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).分子亚型转移性大细胞神经内分泌癌(LCNEC)中 PD-L1 表达的流行率和预后价值。
Lung Cancer. 2019 Apr;130:179-186. doi: 10.1016/j.lungcan.2019.02.022. Epub 2019 Feb 21.
4
Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer.非小细胞肺癌患者肿瘤细胞和肿瘤浸润免疫细胞 PD-L1 表达的临床病理相关性。
J Immunother. 2019 Jan;42(1):23-28. doi: 10.1097/CJI.0000000000000249.
5
PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes.非小细胞肺癌包括各种腺癌亚型中的程序性死亡受体配体1(PD-L1)表达
Ann Thorac Cardiovasc Surg. 2019 Feb 20;25(1):1-9. doi: 10.5761/atcs.oa.18-00163. Epub 2018 Oct 3.
6
Concordance of PD-L1 Expression Between Core Biopsy and Resection Specimens of Non-Small Cell Lung Cancer.非小细胞肺癌核心穿刺活检与切除标本中 PD-L1 表达的一致性。
Am J Surg Pathol. 2018 Aug;42(8):1090-1094. doi: 10.1097/PAS.0000000000001085.
7
Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma.程序性细胞死亡配体 1(PD-L1)的表达与肺腺癌中的 RAS/TP53 突变相关。
Lung Cancer. 2018 Apr;118:62-68. doi: 10.1016/j.lungcan.2018.02.005. Epub 2018 Feb 6.
8
Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas.PD-L1 的表达与非小细胞肺癌的多形性形态和组织学模式相关。
Histopathology. 2018 May;72(6):1024-1032. doi: 10.1111/his.13466. Epub 2018 Mar 5.
9
Biology of invasive mucinous adenocarcinoma of the lung.肺侵袭性黏液腺癌的生物学
Transl Lung Cancer Res. 2017 Oct;6(5):508-512. doi: 10.21037/tlcr.2017.06.10.
10
PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung.肺鳞状细胞癌和腺癌中程序性死亡受体配体1(PD-L1)的表达
Radiol Oncol. 2017 Sep 14;51(3):357-362. doi: 10.1515/raon-2017-0037. eCollection 2017 Sep.

一种对非小细胞肺癌组织学分型与程序性死亡配体 1 表达相关性的定量评估,包括各种腺癌亚型:一项横断面研究。

A quantitative evaluation of the histological type dependence of the programmed death-ligand 1 expression in non-small cell lung cancer including various adenocarcinoma subtypes: a cross-sectional study.

机构信息

Department of General Thoracic Surgery, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan.

Department of Laboratory Medicine and Pathology, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan.

出版信息

Jpn J Clin Oncol. 2022 Mar 3;52(3):281-285. doi: 10.1093/jjco/hyab202.

DOI:10.1093/jjco/hyab202
PMID:34969085
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8894954/
Abstract

The association between non-small cell lung cancer histology and programmed death-ligand 1 expression remains controversial. We retrospectively analyzed histological dependence of the programmed death-ligand 1 expression by a multiple regression analysis of 356 non-small cell lung cancer patients. The programmed death-ligand 1 expression patterns of adenocarcinoma were consistent with a pathological predominant growth pattern as a reference to papillary adenocarcinoma: minimally invasive adenocarcinoma[partial regression coefficient (B), 0.17; 95% confidence interval, 0.05-0.59], lepidic adenocarcinoma (B, 0.46; 95% confidence interval, 0.23-0.90), acinar adenocarcinoma (B, 1.98; 95% confidence interval, 1.05-3.76) and solid adenocarcinoma (B, 5.11; 95% confidence interval, 2.20-11.9). In histology other than adenocarcinoma, the programmed death-ligand 1 expression tended to be high with poor differentiation: adenosquamous carcinoma (B, 4.17; 95% confidence interval, 1.05-16.6), squamous cell carcinoma (B, 4.32; 95% confidence interval, 2.45-7.62) and pleomorphic carcinoma (B, 13.0; 95% confidence interval, 4.43-38.2). We showed quantitatively that the programmed death-ligand 1 expression in non-small cell lung cancer tended to be clearly histology-dependent, with more poorly differentiated histology showing a higher expression.

摘要

非小细胞肺癌组织学与程序性死亡配体 1 表达之间的关系仍存在争议。我们通过对 356 例非小细胞肺癌患者的多元回归分析,回顾性分析了程序性死亡配体 1 表达的组织学依赖性。腺癌的程序性死亡配体 1 表达模式与以乳头状腺癌为主的病理生长模式一致:微浸润性腺癌[偏回归系数(B),0.17;95%置信区间,0.05-0.59]、贴壁性腺癌(B,0.46;95%置信区间,0.23-0.90)、腺泡性腺癌(B,1.98;95%置信区间,1.05-3.76)和实体性腺癌(B,5.11;95%置信区间,2.20-11.9)。在非腺癌组织学中,分化较差的程序性死亡配体 1 表达倾向于升高:腺鳞癌(B,4.17;95%置信区间,1.05-16.6)、鳞状细胞癌(B,4.32;95%置信区间,2.45-7.62)和多形性癌(B,13.0;95%置信区间,4.43-38.2)。我们定量地表明,非小细胞肺癌中程序性死亡配体 1 的表达倾向于明显依赖于组织学,分化越差表达越高。